A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma

Am J Hematol. 2022 Feb 1;97(2):E54-E58. doi: 10.1002/ajh.26420. Epub 2021 Nov 30.

Authors

Robert Frank Cornell¹, Rachid Baz², Joshua R Richter³, Adriana Rossi⁴, Dan T Vogl⁵, Christine Chen⁶, Chaim Shustik⁷, Mariano J Alvarez⁸, Yao Shen⁸, T J Unger⁹, Osnat Ben-Shahar⁹, Hongwei Wang⁹, Erkan Baloglu⁹, William Senapedis⁹, Xiwen Ma⁹, Yosef Landesman⁹, Xiang Bai⁹, Justin Bader⁹, Hongmei Xu⁹, Tracey Marshall⁹, Hua Chang⁹, Christopher J Walker⁹, Jatin Shah⁹, Sharon Shacham⁹, Michael G Kauffman⁹, Craig C Hofmeister¹⁰

Affiliations

¹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
² Moffitt Cancer Center, Tampa, Florida, USA.
³ Hackensack University John Theurer Cancer Center, Hackensack, New Jersey, USA.
⁴ Weill Cornell Medical College Myeloma Center, New York, New York, USA.
⁵ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁶ UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
⁷ McGill University Health Centre, Montreal, Quebec, Canada.
⁸ DarwinHealth Inc., New York, New York, USA.
⁹ Karyopharm Therapeutics Inc, Newton, Massachusetts, USA.
¹⁰ Ohio State University, Columbus, Ohio, USA.

PMID: 34817872
DOI: 10.1002/ajh.26420

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Administration, Oral
Aged
Antineoplastic Agents* / administration & dosage
Antineoplastic Agents* / adverse effects
Antineoplastic Agents* / therapeutic use
Female
Humans
Male
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local* / drug therapy
Treatment Outcome

Substances

Antineoplastic Agents
Eltanexor